Stay updated with breaking news from Nexalin Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device
The FDA has agreed on the design for Nexalin's planned clinical studies of the Gen-3 HALO Clarity, targeting insomnia and anxiety.
HOUSTON, TX, May 22, 2024 -- Nexalin Technology, Inc. is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury Registry Coalition ....
HOUSTON, TEXAS, April 25, 2024 -- Nexalin Technology, Inc. announced that the Company received notice from The Nasdaq Stock Market on April 23, 2024, notifying the Company that it has regained...
Nexalin Technology completed the first full production test run of its Gen-3 HALO Clarity insomnia neurostimulator.